These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11237270)

  • 1. Prevention of secondary osteoporosis postmenopause in hemiplegia.
    Ikai T; Uematsu M; Eun SS; Kimura C; Hasegawa C; Miyano S
    Am J Phys Med Rehabil; 2001 Mar; 80(3):169-74. PubMed ID: 11237270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I; Herd RJ; Blake GM; Balena R
    Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
    Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
    Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
    Watts NB; Becker P
    Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
    Diamond T; McGuigan L; Barbagallo S; Bryant C
    Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A; Snelder AA; Mulder H
    Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
    Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
    J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy.
    Pouilles JM; Tremollieres F; Roux C; Sebert JL; Alexandre C; Goldberg D; Treves R; Khalifa P; Duntze P; Horlait S; Delmas P; Kuntz D
    Osteoporos Int; 1997; 7(3):213-8. PubMed ID: 9205633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.
    Iwamoto J; Takeda T; Ichimura S
    J Orthop Sci; 2001; 6(6):487-92. PubMed ID: 11793169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
    Mortensen L; Charles P; Bekker PJ; Digennaro J; Johnston CC
    J Clin Endocrinol Metab; 1998 Feb; 83(2):396-402. PubMed ID: 9467547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
    Verit FF; Geyikli I; Yazgan P; Celik A
    Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
    Uretmen S; Gol M; Cimrin D; Irmak E
    Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
    Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
    Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of early postmenopausal bone loss with cyclical etidronate.
    Adami S; Bruni V; Bianchini D; Becorpi A; Lombardi P; Campagnoli C; Ferrari A; Marchesoni T; Balena R
    J Endocrinol Invest; 2000 May; 23(5):310-6. PubMed ID: 10882149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to alendronate in osteoporosis after previous treatment with etidronate.
    Fairney A; Kyd P; Thomas E; Wilson J
    Osteoporos Int; 2000; 11(7):621-5. PubMed ID: 11069197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
    J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between serum leptin concentrations and bone mineral density as well as biochemical markers of bone turnover in women with postmenopausal osteoporosis.
    Shaarawy M; Abassi AF; Hassan H; Salem ME
    Fertil Steril; 2003 Apr; 79(4):919-24. PubMed ID: 12749431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.